TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $30,061,363 | -13.8% | 1,957,120 | +26.2% | 0.04% | -18.2% |
| Q1 2023 | $34,870,790 | +298476.8% | 1,550,502 | +179.2% | 0.04% | +158.8% |
| Q4 2022 | $11,679 | -99.9% | 555,366 | +34.6% | 0.02% | +13.3% |
| Q3 2022 | $10,164,000 | +18.8% | 412,511 | +16.9% | 0.02% | +25.0% |
| Q2 2022 | $8,554,000 | +6.2% | 353,025 | +13.0% | 0.01% | +33.3% |
| Q1 2022 | $8,054,000 | -21.7% | 312,546 | -5.7% | 0.01% | -10.0% |
| Q4 2021 | $10,292,000 | +19.8% | 331,588 | -6.4% | 0.01% | +11.1% |
| Q3 2021 | $8,588,000 | – | 354,163 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Deep Track Capital, LP | 7,370,000 | $113,203,200 | 5.24% |
| Finepoint Capital LP | 761,721 | $11,700,035 | 4.05% |
| Kynam Capital Management, LP | 1,454,730 | $22,344,653 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 441,019 | $6,769,642 | 2.06% |
| MPM BioImpact LLC | 552,846 | $8,491,715 | 1.71% |
| ARMISTICE CAPITAL, LLC | 7,450,000 | $114,432,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 435,313 | $6,686,408 | 1.12% |
| Octagon Capital Advisors LP | 495,000 | $7,603,200 | 1.06% |
| Orbimed Advisors | 2,118,100 | $32,534,016 | 0.59% |
| Rock Springs Capital Management LP | 1,527,720 | $23,465,779 | 0.56% |